Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QN45 | ISIN: US0053291078 | Ticker-Symbol: 978
Frankfurt
06.06.25 | 15:29
1,510 Euro
-7,36 % -0,120
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ADAGENE INC ADR Chart 1 Jahr
5-Tage-Chart
ADAGENE INC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,7201,78022:59
1,7201,76022:00

Aktuelle News zur ADAGENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Adagene Inc.: Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting410CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite...
► Artikel lesen
ADAGENE Aktie jetzt für 0€ handeln
22.05.Adagene Inc. - 6-K, Report of foreign issuer1
09.05.Adagene announces $200M mixed shelf offering1
28.04.Adagene Inc.: Adagene Appoints John Maraganore, Ph.D. as Executive Advisor1
23.04.Adagene Inc.: Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting2
24.03.Adagene ADR Non-GAAP EPS of -$0.51 beats by $0.07, revenue of $0.1M misses by $9.4M1
24.03.Adagene Inc. Full Year Loss Increases, But Beats Estimates293BEIJING (dpa-AFX) - Adagene Inc. (ADAG) revealed Loss for its full year that decreased from the same period last year and beat the Street estimates.The company's earnings totaled -$33.42 million...
► Artikel lesen
24.03.Adagene Inc. - 20-F, Annual and transition report of foreign private issuers2
24.03.Adagene Inc.: Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update1.141Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked...
► Artikel lesen
24.03.Adagene Inc. - 6-K, Report of foreign issuer2
13.03.Adagene Inc.: Adagene to Present at 11th Annual Immuno-Oncology 360° Summit3
27.02.Adagene Inc.: Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer165- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE...
► Artikel lesen
27.01.Adagene Announces New Phase 1b/2 Data For Muzastotug Plus Keytruda In Colorectal Cancer307BEIJING (dpa-AFX) - Adagene Inc. (ADAG), Monday announced updated data from Phase 1b/2 study of Muzastotug in combination with Merck's Keytruda for the treatment of microsatellite stable colorectal...
► Artikel lesen
27.01.Adagene reports positive colorectal cancer trial results3
27.01.Adagene meldet positive Ergebnisse bei Darmkrebsstudie8
27.01.Adagene Inc. - 6-K, Report of foreign issuer3
21.01.Adagene to present new ADG126 clinical data at ASCO-GI1
21.01.Adagene präsentiert neue klinische Daten zu ADG126 auf der ASCO-GI2
21.01.Adagene Inc.: Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium2
16.09.24Adagene Reports Encouraging Data From Phase 1b/2 Study Of ADG126 Plus Keytruda In Colorectal Cancer323BEIJING (dpa-AFX) - Adagene Inc. (ADAG) Monday announced new data from an ongoing phase 1b/2 trial of Adagene's ADG126 in combination with Merck's Keytruda for the treatment of colorectal cancer.The...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1